Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
West Pharmaceutical Services, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $25.3B | |
|---|---|---|
| Revenue (ttm) | 3.3B | |
| Net income (ttm) | 564.9M | |
| EPS (ttm) | $7.81 | |
| Shares out | 70.4M | |
| P/E (trailing) | 51.7x | |
| P/E (forward) | 37.5x | |
| Dividend | $1.04 (0.26%) | |
| Volume | 657,424 | |
| Beta | 1.12 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.83B | $2.89B | $2.95B | $2.89B | $3.07B | +2.1% |
| Gross profit | $1.18B | $1.14B | $1.13B | $998.5M | $1.10B | -1.6% |
| Operating income | $752.3M | $734.0M | $676.0M | $569.9M | $584.9M | -6.1% |
| Net income | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M | -7.1% |
| EPS (diluted) | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 | -5.9% |
| EBITDA | $879.7M | $808.1M | $844.1M | $743.8M | $770.6M | -3.3% |
| R&D | $52.8M | $58.5M | $68.4M | $69.1M | $74.3M | +8.9% |
| SG&A | $362.8M | $316.9M | $353.4M | $338.5M | $393.6M | +2.1% |
Recent company headlines from major financial publishers.
The base case projects intrinsic Fair value at $191.60 (representing an implied return of -46.7% from $359.51 (as of 2026-10-08)). Under a 65.0% probability weighting, the target is $191.60, delivering an expected return of -46.7%. This reflects steady biologics mix shift, commercial ramp-up at Grand Rapids and Dublin, and gradual margin normalization toward terminal expectations.
The bull case models an upside target of $247.73 with an estimated probability of 15.0%, representing a return of -31.1% relative to $359.51 (as of 2026-10-08). In this scenario, accelerated global adoption of GLP-1 therapies and complex biologics drives high-teens proprietary volume growth, while rapid operational execution at Dublin and Grand Rapids maximizes fixed-overhead absorption and lifts operating margins toward Potential value of $247.73.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 8.6% | $206 | $210 | $214 | $219 | $225 |
| 9.1% | $195 | $198 | $202 | $206 | $211 |
| 9.6% | $186 | $189 | $192 | $195 | $199 |
| 10.1% | $177 | $180 | $182 | $185 | $188 |
| 10.6% | $170 | $172 | $174 | $177 | $179 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
